Adaptive Trial Design
An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.
Înregistrare sursă
Citările sunt copiate integral din înregistrarea sursă a metodei. Nu se inferă nicio verificare la nivel de afirmație din acestea.
- Pocock, S. J. (2005). Current issues in the design and interpretation of clinical trials. BMJ, 330(7500), 1118–1121. · URL
- Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., ... & Wason, J. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 16(1), 29. · DOI 10.1186/s12916-018-1017-7
- FDA (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. US Food and Drug Administration. · URL
Afirmații curate
Afirmațiile sunt stocate în registrul dovezilor, fiecare cu propria evaluare.
Această vizualizare nu inventează o evaluare a afirmației dacă registrul nu conține una.
Metode conexe
Generate din graful metodelor și afișate ca relații sugerate automat — nu se inferă nicio afirmație de dovadă.